Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study

Verona Pharma PLC VRNA has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints.
Dose-ordered improvement in lung function was observed and statistically significant at peak and over the 12-hour dosing interval compared with placebo, thus supporting twice-daily dosing.
An increase in lung function measured by peak forced expiratory volume in one second (FEV1) were 205 mL, 277mL, and 326mL for 300 µg, 1000 µg, and 3000 µg dose, respectively.
Ensifentrine pMDI formulation was well tolerated at each dose with an adverse event profile similar to placebo.
The drug candidate is also under development in hospitalized COVID-19 patients, with results expected in Q2 this year.
Price Action: VRNA shares are higher by 13.4% at $8.96 in the pre-market session on the last check Tuesday.